Reported about 1 year ago
Cassava Sciences (SAVA) is establishing a committee to investigate two senior employees following a US probe into fraud and a researcher associated with Cassava being indicted for fabricating Alzheimer's drug trial results. The company's stock was temporarily halted due to volatility after dropping over 40% in light of the allegations, causing concern among investors and analysts.
Source: YAHOO